Ustekinumab NPPA applications for Crohn’s disease and/or ulcerative colitis

5 November 2020

Dear [name and contact details withheld]

REQUEST FOR INFORMATION

Thank you for your request dated 22 October 2020 under the Official Information Act 1982 (OIA), in follow-up to our response to OIA 2020-21-029, for information relating to Named Patient Pharmaceutical Assessment (NPPA) applications for ustekinumab. You asked:

• how many of the 48 NPPA applications for ustekinumab were for patients with either Crohn's disease or ulcerative colitis.

In response to your request, I can advise, of the 48 NPPA applications PHARMAC has received for ustekinumab, 19 were for the treatment of patients with Crohn’s disease and/or ulcerative colitis.

We trust that this information answers your queries. We are making our information more freely available, so we will now publish selected OIA responses (excluding personal details) on our website.  Please get in touch with us if you have any questions about this.

Yours sincerely

Rachel Read
Manager, Policy and Government Services